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ABSTRACT 
       Dysregulation of hepatic glucose production (HGP) serves as a major underlying mechanism 
for the pathogenesis of type 2 diabetes mellitus (T2D). The pancreatic hormone glucagon 
increases, and insulin suppresses HGP, controlling blood glucose homeostasis. The forkhead 
transcription factor Foxo1 promotes HGP through increasing expression of genes encoding the 
rate-limiting enzymes responsible for gluconeogenesis. We previously established that insulin 
suppresses Foxo1 by Akt-mediated phosphorylation of Foxo1 at Ser256 in human hepatocytes. 
In this study, we found a novel Foxo1 regulatory mechanism by glucagon, which promotes 
Foxo1 nuclear translocation and stability via cAMP- and protein kinase A (PKA)-dependent 
phosphorylation of Foxo1 at Ser276.  Replacing Foxo1-S276 with alanine (A) or aspartate (D) to 
block or mimic phosphorylation, respectively, markedly regulates Foxo1 stability and nuclear 
localization in human hepatocytes. To establish in vivo function of Foxo1-Ser276 
phosphorylation in glucose metabolism, we generated Foxo1-S273A and Foxo1-S273D knock-in 
(KI) mice. The KI mice displayed impaired blood glucose homeostasis, as well as the basal and 
glucagon-mediated HGP in hepatocytes.  Thus, Foxo1-Ser276 is a new target site identified in 
control of Foxo1 bioactivity and associated metabolic diseases. 
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INTRODUCTION 
    Glucagon and insulin are the most important pancreatic hormones in target tissues, such as 
liver, in control of glucose homeostasis in the body in response to food intake (1,2). During the 
fasting state, glucagon is secreted from the pancreatic α-cells to elevate blood glucose through 
stimulation of gluconeogenesis and glycogenolysis, protecting the body from hypoglycemia (3). 
However, an excess of blood glucagon level is present in animals and patients with diabetes 
mellitus, stimulating excessive hepatic gluconeogenesis and contributing to diabetic 
hyperglycemia (1,4-7).   
     Glucagon exerts its function through binding to the glucagon receptor (GCGR), a G-protein 
coupled receptor. Upon binding to glucagon, GCGR in the cell membrane activates adenylate 
cyclase to elevate intracellular cyclic adenosine monophosphate (cAMP) and subsequently 
activates PKA signaling (1,2).  PKA regulates the metabolic enzymes or gene expression for 
glycogenolysis and gluconeogenesis, including glycogen phosphorylase, glucose-6-phosphatase 
catalytic subunit (G6pc), and phosphoenolpyruvate carboxykinase-1 (Pck1) (8), increasing blood 
glucose. Importantly, recent studies demonstrated that inhibition of GCGR by a genetic approach 
or chemical administration in mice significantly decreases the blood glucose and completely 
prevents streptozotocin (STZ)-induced hyperglycemia in type 1 diabetes mellitus (T1D) (1), 
suggesting that glucagon-mediated hepatic glucose production (HGP) or gluconeogenesis is a 
potential target for therapeutic intervention of diabetes mellitus (9,10).  
   Gluconeogenesis is suppressed by insulin involving in the gene transcriptional regulation in 
the nucleus. Foxo1, a member of the O-class of forkhead/winged helix transcription factor 
(Foxo), is an important component of insulin signaling cascades in regulating cellular growth, 
differentiation and metabolism (11). Our and other studies demonstrated that Foxo1 enhances 
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gene transcription of the rate-limiting enzymes responsible for gluconeogenesis, including G6pc 
and Pck1, through interaction with a conserved insulin-responsive element on the promoter 
region of the target genes (12-14), and increases HGP (11,15-17). However, insulin suppresses 
Foxo1 by the insulin receptor substrate1, 2 (IRS1, 2)-dependent activation of Akt that 
phosphorylates Foxo1 at Ser256 in human hepatocytes, which is equivalent to mouse Foxo-S253, 
promoting Foxo1 nuclear export and/or degradation and then decreasing HGP and blood glucose 
(18-21).  
    Foxo1 protein is stabilized in the liver of fasting mice when insulin decreases and glucagon 
increases in the blood circulation. Our early studies indicate that Foxo1 may partially mediate the 
effect of cAMP, a second messenger of glucagon, or glucocorticoid-induced expression of genes 
encoding gluconeogenic enzymes, such as G6pc and Pck1 (22,23). Recently, a calcium-sensing 
enzyme, CaMKII is shown to increase seven non-Akt phosphorylation sites of Foxo1, mediating 
the action of glucagon and cAMP signaling and enhancing Foxo1 nuclear localization and 
hepatic glucose production, but detailed phosphorylation sites involving in glucagon or cAMP 
signaling remain elusive in vivo (24). In this study, we hypothesize that Foxo1 may play a role in 
the action of glucagon in control of HGP or gluconeogenesis, and investigated the molecular and 
physiological mechanism of Foxo1 regulation by glucagon via PKA with the aim of better 
understanding the fundamentals of blood glucose homeostasis and pathogenesis of diabetes 
mellitus.   
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METHODS 
In vitro kinase assay and liquid chromatography-mass spectrometry (LC-MS). To determine 
whether Foxo1 is directly phosphorylated by PKA, we performed in vitro kinase assay, in which 
20 µg of recombinant Foxo1-GST fusion protein was purchased from Millipore Inc as previously 
described (18).  The purified Foxo1-GST recombinant protein was incubated with 5 units of 
recombinant PKAc (Upstate) for 1 h, at 30
◦
C, in 50 µl reaction buffer (25 mM Tris-HCl, pH 7.0, 
1 mM EGTA, 0.5 mM EDTA, 0.5 mM β-mercaptoethanol, and 3 mM magnesium acetate) with 
or without 0.1 mM ATP.  The protein bands of interest in the SDS-PAGE gel were incised and 
prepared for LC-MS analysis, as described in the supplemental material.   
DNA mutagenesis. Plasmid DNA expressing human Foxo1-WT was previously described (12). 
Oligos specific for human Foxo1-S153A, Foxo1-S153D, Foxo1-S276A, or Foxo1-S256D were 
designed and QuickChange
TM
 Site-Directed Mutagenesis kit was purchased (Stratagene, La 
Jolla) and mutant sites were confirmed by DNA sequencing.  
Mice. All animal experiments were performed according to procedures approved by Texas A&M 
University Institutional Animal Care and Use Committee. The floxed Foxo1 mice (Foxo1
L/L
) 
(25), and albumin-Cre mice were previously described (26). All the mice on a C57BL/6 and 129 
Sv mixed background were maintained on regular chow (Prolab Isopro 5P76). Foxo1-S273A and 
Foxo1-S273D knock-in (KI) mice were generated using the CRISPR/Cas9 approaches (27) and 
the microinjection and mouse colonies production performed by Cyagen Biosciences Inc. (Santa 
Clara, CA, contract number: NTMCN-150310-AML-01). The founder mice were backcrossed to 
C57/BL6 mice and F3 offspring male mice were used for analysis. The tail DNA of pups was 
genotyped by PCR and then confirmed by DNA sequencing analysis. Db/db mice were 
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purchased from Jackson laboratory (Bar Harbor, NM). If not specified elsewhere, all the mice 
were male at the ages of 8-12 weeks. For high fat diet (HFD) induced insulin resistant mouse 
model, 8-10 weeks old male mice were fed with HFD (42% kcal from fat, Envigo, TD.88137) or 
control low fat diet (LFD, 13% kcal from fat, Envigo, TD08485) for 6 months.  For glucagon 
tolerant tests, mice after 18 h fasting were i.p. injected with glucagon of 16 µg/kg body weight  
and blood glucose were measured with a glucometer (Elite XL, Bayer). The dose of glucagon 
used was based on a recent report (28).   
Generation of phosphospecific antibodies for Foxo1. We synthesized two peptides of human 
Foxo1 corresponding to residues 143-162 (GPLAGQPRKSpSSSRRNAWGN), and 265-285 
(KSRSRAAKKKApSLQSGQEGAG), where p indicates the site of phosphorylation (S153 and 
S276). The peptides were conjugated to both keyhole limpet hemocyanin and bovine serum 
albumin and used to immunize rabbits at Covance, Denver, PA (Custom Immunology Service, 
CRPQ20383-01P), as previously described (18).  
Blood chemistry and metabolic analysis. Serum were analyzed for insulin (Crystal Chem.) and 
glucagon (Alpco) using commercial protocol and reagents. Blood glucose was measured using a 
glucometer (Bayer).  For glucagon stimulation experiments, 8 to 12-week old mice were subject 
an 18 h fasting and injected intraperitoneally (i.p) by glucagon (pharmaceutical grade, 0.25 
mg/kg body weight) and blood glucose monitored. For GCGR antagonist injection, 6 h fasting 
control mice were i.v. injected with GCGR antagonist ([des-His
1
, Glu
9
]-glucagon amide) 
(1mg/kg body weight). 
Protein analysis and Western-blotting. Proteins were prepared from cells or livers, resolved by 
SDS-PAGE and transferred to nitrocellulose membrane for immunoblotting analysis using 
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specific antibodies, as previously described (29). The signal intensity was measured and 
analyzed by NIH Image J software.  
Nuclear and cytoplasmic protein extraction. Nuclear and cytoplasmic proteins from HepG2 
were extracted with NE-PER nuclear (NER) and cytoplasmic (CER-I and CER-II) extraction 
reagent (Pierce), as previously described (29).  
Gluconeogenesis, glycogenolysis, and HGP assay. The primary mouse hepatocytes were 
isolated from 8-12 week-old mice via 0.05% collagenase (type1, Worthington) and cultured as 
previously described (16). For HGP assays, freshly isolated hepatocytes were resuspended in 
DMEM with 2% FBS for 4 h, then rinsed with PBS, and cultured in HGP buffer (118 mM NaCl, 
2.5 mM CaCl2, 4.8 mM KCl, 25 mM NaHCO3, 1.1 mM KH2PO4, 1.2 mM MgSO4, 10 µM 
ZnSO4, 0.6% BSA, 10 mM HEPES, 10 mM sodium DL-lactate, and 5 mM pyruvate, pH 7.4) in 
the presence or absence of 100 nM glucagon or 8-Br-cAMP. Cell culture medium was collected 
at 3 and 6 h, and glucose in the medium measured according to the manufacturer's protocol, 
using Amplex
®
 Red Glucose Assay (Invitrogen) (30,31). For glycogenolysis assay, lactate and 
pyruvate in the HGP buffer were removed and glucose release into the medium measured after 
treatments.  
Quantitative real-time PCR. RNA was extracted with Trizol reagent (Invitrogen), cDNA 
synthesis used the Super-Script first-strand synthesis system (Bio-Rad), and gene expression was 
measured with the SYBER Green Supermix system (Bio-Rad), as previously described (29).  
Gene transfection and luciferase reporter gene assay and confocal fluorescent microscope. 
HepG2 cells were cultured with DMEM with 10% FBS for 6 h. Cell culture were then subjected 
to Lipofectamine® 3000 (Life technologies) with plasmids according to manufacturer’s 
instruction. The dual-luciferase reporter assay system from Promega was purchased and 
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luciferase activity measured with an Optocomp-I luminometer (MGM Instrument), and cells 
expressing eGFP and eGFP-Foxo1 visualized with the confocal microscope (Leica) and 
calculated as previously described (32). 
Statistical analysis. The comparison of differences between two groups was performed using a 
Student’s two-tailed t test to determine the significance (26).  ANOVA tests were used when 
comparing two groups among multiple groups. All data are presented as mean+ SEM. P<0.05 
was considered statistically significant.  
RESULTS 
Hepatic Foxo1 is involved in glucagon-induced glucose production in mice 
        Previous studies from our group and others have shown that liver-specific Foxo1 knockout 
mice (L-F1KO) or hepatic Foxo1 suppression exhibited a 15-20% reduction in blood glucose as 
compared to control mice (16,17,33). To determine whether Foxo1 is involved in the action of 
glucagon-mediated blood glucose homeostasis, we administered glucagon intraperitoneally (i.p.) 
in L-F1KO and control fed-mice. Glucagon significantly increased blood glucose by 32% in 
control mice 60 min after glucagon injection, but the increased potential in L-F1KO mice was 
21%, with a significant reduction compared to control mice (Fig. 1A). We next performed the 
glucagon tolerance test in the mice in the fasting state. Both control and L-F1KO mice exhibited 
nearly a 1.7-fold elevation in blood glucose 15 min after glucagon injection. Importantly, the 
ability of blood glucose increase was maintained in 60 min after glucagon injection in control 
mice, however L-F1KO mice exhibited a 50% reduction in blood glucose after glucagon 
stimulation compared with control mice (P<0.05, Fig. 1B). Gene expression analysis indicated 
that glucagon stimulated hepatic gene transcriptional levels of Igfbp-1, G6pc and Pck1 in control 
mice by 4.4-, 2.6-, and 2.0-fold, respectively. However, glucagon stimulation on the Igfbp-1, 
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G6pc, and Pck1 were 3.2-,  2.0-, and 1.8 -fold, respectively, in L-F1KO liver, exhibiting 
significant reductions compared to control (Fig. 1, C-E).  
      To determine whether Foxo1 deficiency impairs glucagon-mediated glucose production via 
glycogenolysis and gluconeogenesis in an autonomous manner in hepatocytes, we measured 
HGP with glucagon treatment in primary hepatocytes isolated from L-F1KO and control mice. 
Glucagon significantly increased HGP by 42 % in control hepatocytes, and by 35% in L-F1KO 
hepatocytes, exhibiting a 28% reduction in L-F1KO cells (Fig. 1F).  Both glycogenolysis and 
gluconeogenesis contribute to HGP, L-F1KO cells exhibited a 50% reduction in glucagon-
stimulated gluconeogenesis compared to control (46% stimulation in control vs. 23% in L-
F1KO, p<0.01). Glucagon significantly increased glycogenolysis by 21% in control cells, L-
F1KO hepatocytes had no blockage for glucagon, even though the basal level of glycogenolysis 
was 29% lower in L-F1KO than control cells (71 + 4.2 µmol/h/g protein vs. 50 + 4.9 µmol/h/g 
protein, P<0.01) (Fig. 1F). Taken together, these data indicate that Foxo1 deficiency impaired 
glucagon-induced liver gene expression, gluconeogenesis, and blood glucose.      
Insulin and glucagon exhibit an opposite effect on Foxo1 stability in hepatocytes 
      We next examined the effect of insulin versus glucagon on Foxo1 regulation in hepatocytes. 
HepG2 cells were cultured and treated the hormones over a 6 h time course. Insulin treatment for 
3 h significantly reduced total Foxo1 protein by 20%. However, glucagon treatment for 3 h 
significantly increased total Foxo1 protein by 1.7-fold (Fig. 2, A and B). The phosphorylation 
level of Foxo1 at S256 was increased 2.5-fold by insulin for 3 h treatment and persisted up to 6 h, 
while glucagon barely stimulated Foxo1-S256 phosphorylation even that the phosphorylation 
was slightly reduced at 3 h of treatment (Fig. 2, A and C). Insulin treatment for 15 min increased 
by 23-fold on Akt phosphorylation at T308, which was increased 5-fold by glucagon when 
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compared to the basal level of Akt phosphorylation in cells (Fig. 2, A and D). By contrast, 
insulin barely increased phosphorylation of cAMP-responsive element binding protein (CREB) 
at S133, a target of PKA, but glucagon treatment for 15 min significantly increased CREB-S133 
phosphorylation by 1.5-fold without changing the total CREB protein level (Fig. 2, A, B and E). 
Moreover, Foxo1 mRNA levels were unaffected by glucagon in HepG2 cells (Fig. 2F). These 
results prompted us to hypothesize that glucagon may promote Foxo1 stability through activation 
of PKA and control Foxo1 target gene expression, impelling us to assess the impact of Foxo1 in 
glucagon-regulated HGP in vivo. 
PKA stimulates and Akt inhibits the Foxo1-regulated reporter gene activity 
      PKA and Akt serve as important downstream effectors in glucagon and insulin signaling, 
respectively, in control of glucose homeostasis (15,34). In order to determine whether PKA 
affects Foxo1-mediated gene transcriptional activity in hepatocytes, we transfected HepG2 cells 
with the Igfbp-1-luciferase reporter gene construct with plasmid DNA expressing control green 
fluorescent protein (GFP), the catalytic subunit of PKA (PKAc), or constitutively active Akt 
(Myr-Akt), and then luciferase activities were measured. Overexpression of PKAc alone 
increased the basal promoter activity by at least 2-fold, whereas over expression of active form 
of Akt (MyrAkt) inhibited the promoter activity by 55% (Fig. 3A).  Moreover, expression of 
Foxo1 alone increased Igfbp-1 promoter activity by 2.9-fold, and co-expressing PKAc and 
Foxo1 resulted in a robust increase of Igfbp-1 promoter activity, at least by more than 10-fold. 
By contrast, co-overexpression of Myr-Akt and Foxo1 almost completely diminished the Foxo1-
stimulated Igfbp-1 promoter activity (Fig. 3A). Together, these data suggest that PKA had an 
additive effect on promoting Foxo1-stimulated Igfbp-1 promoter activity.   
Identification of novel serine/threonine phosphorylation sites of Foxo1 by PKA 
Page 11 of 46 Diabetes
11 
      Analysis of Foxo1 phosphorylation sites (http://scansite.mit.edu) revealed that human Foxo1 
contains three PKA consensus sequences (R/KXRT/S, R-Arginine, K-Lysine, X-any amino 
acid), located at Ser153, Thr182, and Ser276, which are evolutionarily conserved across species 
(Fig. 3B). We hypothesize that glucagon-activated PKA phosphorylates Foxo1 via these putative 
PKA phosphorylation sites and enhances Foxo1 stability and transcriptional activity.  
      Next, we performed in vitro kinase assay to determine whether PKA can directly 
phosphorylate Foxo1. Glutathione-S-transferase-fused Foxo1 (Foxo1-GST) and active PKA 
catalytic subunit were incubated in a protein kinase assay buffer system and then resolved by 
SDS-PAGE followed by the Coomassie-brilliant blue staining. Phosphorylated Foxo1 fragment 
(60 kDa) by PKAc slightly upshifted in mobility (Fig. 3C). The Foxo1-GST protein (105 kDa) 
and Foxo1 fragment (60 kDa) were incised from the gel and subjected to LC-MS/MS analyses. 
The results from Mascot analysis of mass spectrometry (MS) of PKAc with/without ATP-treated 
samples indicated a presence and high score for Foxo1-S276 phosphorylation, a low score for 
Foxo1-S153 phosphorylation, and no presence and score for T182 phosphorylation (Fig. 3D). 
Based on these results, we generated the phosphospecific antibody against human Foxo1-S276 or 
Foxo1-S153, which is equivalent to mouse Foxo1-S273 or S150, respectively. In HepG2 cells, 
glucagon significantly stimulated the phosphorylation of Foxo1-S273 and S153 by 2.5-fold and 
1.5-fold, respectively (Fig. 3E). The phosphorylation of S276 and S153 by glucagon was blocked 
when PKA catalytic subunit C (PKACB) was knockdown by siRNA(Fig. 3E). The knockdown 
of PKA markedly decreased glucagon-stimulated CREB phosphorylation and Foxo1 protein 
level, suggesting that PKA is essential for maintaining Foxo1 protein stability (Fig. 3E). We 
further confirmed these findings in mouse primary hepatocytes, glucagon treatment enhanced the 
phosphorylation of Foxo1 at S273 and S150, as well as total Foxo1 protein levels, while these 
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effects of glucagon were abolished in the cells when treated with H89, a PKA chemical inhibitor 
(Fig. 3F). In mouse liver, glucagon injection resulted in a 3.8-fold increase in Foxo1-S273 
phosphorylation and a 1.6-fold increase in Foxo1-S150 phosphorylation (Fig. 4A). Moreover, we 
administered GCGR antagonist into WT mice and examined whether endogenous Foxo1 protein 
level is regulated by the glucagon receptor in the liver. Intravenous injection of GCGR 
antagonist ([des-His
1
, Glu
9
]-Glucagon amide) resulted in a 20% decrease in blood glucose (Fig. 
4, B and C), as well as a 60% decrease of CREB phosphorylation, 55% decrease in Foxo1-S273 
phosphorylation, and 35% decrease in total Foxo1 protein level, while Foxo1-S150 
phosphorylation was barely affected compared to vehicle treatment (Fig. 4D). These results 
suggest that glucagon signaling via its receptor and PKA stimulates hepatic Foxo1 
phosphorylation at S273, enhancing Foxo1 stability.   
Human Foxo1-S276 phosphorylation promotes Foxo1 nuclear localization 
      We next examined whether the newly identified Foxo1 phosphorylation sites play a role in 
Foxo1 nuclear/cytoplasmic trafficking and stability in cells. We generated plasmid DNA 
expressing GFP-Foxo1-WT (wild-type), GFP-Foxo1-S153A, or GFP-Foxo1-S276A, in which 
serine residue was substituted with an alanine (A) at S153 or S276 to block phosphorylation, 
whereas GFP-Foxo1-S153D or GFP-Foxo1-S276D containing an aspartate (D) substitution to 
mimic phosphorylation by introduction of a negative charge. HepG2 cells were transfected with 
one of these plasmids and then stimulated with 8-Br-cAMP for 15 min prior to confocal imaging.  
In cells that overexpressed Foxo1-WT, Foxo1 localized in both cytoplasm and nucleus at the 
basal level, but cAMP stimulation promoted Foxo1 nuclear localization. However, cAMP-
induced Foxo1-nuclear localization was blocked by S276A mutation, in which overexpressed 
Foxo1-S276A dispersed primarily within the cytoplasm. Conversely, Foxo1-S276D primarily 
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localized in the nucleus (Fig. 5). Compared to Foxo1-WT, Foxo1-S153A or S153D did not 
exhibit distinct differences in Foxo1 subcellular localization in cells, and overexpressed Foxo1-
S153A and 153D were primarily located to the nucleus in responses to cAMP, similar to Foxo1-
WT (Fig. 5). Thus, these results suggest that Foxo1-S276 phosphorylation is crucial for 
mediating cAMP-stimulated Foxo1 nuclear localization.  
    To confirm the Foxo1 subcellular localization upon glucagon or cAMP stimulation, we 
extracted nuclear and cytoplasmic protein from cells for Foxo1 analysis. Glucagon or cAMP 
stimulated endogenous Foxo1 nuclear localization by nearly 3-fold compared to vehicle control 
group (Fig. 6A, P<0.05). By contrast, insulin reduced nuclear total Foxo1 by 25% (Fig. 6A). 
These data indicate that either glucagon or cAMP induced Foxo1 nuclear localization, which is 
distinct from insulin. 
Foxo1-S276 phosphorylation enhances Foxo1 stability in cells 
   We next further focused on Foxo1-S276 phosphorylation in control of Foxo1 stability in 
cells. HepG2 cells were transfected with plasmid DNA that expresses Foxo1-WT, Foxo1-S276A, 
or Foxo1-S276D and then stimulated with glucagon for 30 min followed by nuclear and 
cytoplasmic protein extraction. In Foxo1-WT transfected cells, glucagon increased total Foxo1 
protein in the nucleus by 1.5-fold (Fig. 6, B and C). Importantly, Foxo1-S276D protein, which 
mimics S276 phosphorylation with introduction of a negative charge, increased total Foxo1 
protein abundance in both nucleus and cytoplasm, mimicking the effect of glucagon on Foxo1 
nuclear localization (Fig. 6, B). By contrast, Foxo1-S276A, which contains a substitution of 
alanine, largely prevented glucagon-stimulated Foxo1 nuclear localization (Fig. 6C).  
   To further examine the mechanism of Foxo1-S276 phosphorylation in control of Foxo1 
stability, we transfected with an equal amount of Foxo1 gene construct with HepG2 cells and 
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then treated cells for 8 h with MG132, a 26S proteasome complex inhibitor, preventing Foxo1 
protein ubiquitination or cycloheximide (CHX), a protein synthesis inhibitor, inhibiting Foxo1 
protein synthesis. When Foxo1-WT, Foxo1-S276A, or Foxo1-S276D plasmid DNA was 
transfected, the total Foxo1 protein in Foxo1-S276A group was reduced by 50% compared to 
overexpressed Foxo1-WT (P<0.05, Fig. 6D). However, in the MG132-treated group, the 
reduction of Foxo1-S276A protein was totally prevented and Foxo1-S276A protein was restored 
and stabilized to a normal level when compared to Foxo1-WT, and there was no significant 
difference in total Foxo1 protein levels observed in all the cells transfected with Foxo1-WT, 
S276A, or S276D (Fig. 6D). Moreover, when Foxo1 protein synthesis inhibited by CHX in cells, 
the remaining Foxo1 protein level in Foxo1-S276D group increased by 40%, while decreased by 
44% in Foxo1-S276A group compared to Foxo1-WT group (Fig. 6D).  These data suggest that 
Foxo1-S276 phosphorylation promoted Foxo1 stability, while non-phosphorylation of S276 
enhanced 26S proteasome-dependent degradation of Foxo1.      
Foxo1-S276 phosphorylation impairs insulin-induced Foxo1 ubiquitination and Foxo1 
nuclear export 
  We next determined whether Foxo1-S276 phosphorylation or Foxo1-S276D affects insulin-
induced Foxo1 ubiquitination in cells.  HepG2 cells were transfected with equal amount of 
Foxo1-WT or S276D plasmid DNA together with ubiquitin for 10 h and then stimulated with 
insulin for additional 12 h, total cellular proteins were extracted for analysis. Western-blotting 
analysis revealed that insulin reduced total Foxo1 protein by 50% in Foxo1-WT or S276A 
expressed cells, while the effect of insulin was abolished in cells expressing Foxo1-S276D 
mutant (Fig. 6E).  
Page 15 of 46 Diabetes
15 
 We further assessed whether Foxo1-S276 phosphorylation or Foxo1-S276D affects insulin-
induced Foxo1 nuclear translocation in cells.  HepG2 cells were transfected with equal amount 
of Foxo1-WT or S276D plasmid DNA for 18 h and then stimulated with insulin over a 120-min 
time course. Upon insulin stimulation for either 90 min or 120 min, Foxo1-WT protein was 
primarily located in the cytoplasm (Fig. 7, A-C). Foxo1-S276D protein primarily localized at 
both cytoplasm and nucleus with increased levels compared to Foxo1-WT. However, Foxo1-
S276D largely blocked insulin-stimulated nuclear export, particularly at 120 min treatment of 
insulin (Fig. 7A), which was confirmed by Western-blotting. Moreover, the blotting result 
showed that the cytoplasmic Foxo1-S256 phosphorylation by insulin for 90 or 120 min treatment 
was significantly impaired by S276D mutation since the basal level of Foxo1-S256 
phosphorylation was higher in S276D than WT in cells (Fig. 7, B and C). These results reveal 
that Foxo1-S276 phosphorylation or aspartate mutation promoted Foxo1 nuclear localization and 
stability and impaired the ability of insulin to induce Foxo1 nuclear export and/or degradation, 
which may serve as a mechanism for insulin resistance at the Foxo1 level.   
Foxo1-S273 phosphorylation controls blood glucose homeostasis and hepatic glucose 
production in mice 
      To further explore the physiological function of equivalent human Foxo1-S276 in glucose 
metabolism in mice, we used the CRISPR/Cas9 approach to generate Foxo1-S273A and Foxo1-
S273D knock-in mice, where the endogenous Foxo1-S273 alleles were replaced by alanine (A) 
mutations or aspartate (D) mutations (Fig. S1). All the mice survived with no obvious 
physiological deficiency. The feeding blood glucose increased by 20% in Foxo1-S276
D/D
 mice 
and there was no change in Foxo1-S276
A/A
 mice compared to control. The fasting blood glucose 
increased by 31% in Foxo1-S276
D/D
 mice but decreased significantly by 10% in Foxo1-S276
A/A
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mice (Fig. 8A). Hepatic Igfbp-1 and G6pc mRNA expression significantly increased by 4.5- and 
2.1-fold in the liver of Foxo1-S273
D/D 
compared to control liver, respectively. However, there 
was a 25% reduction for both gene expression in S273
A/A
 liver compared to control liver (P<0.05, 
Fig. 8B). The total Foxo1 protein level in the liver was increased by 2.6-fold in Foxo1-S273
D/D
 
mice, but reduced by 40% in Foxo1-S273
A/A
 mice when compared to control (P<0.05, Fig. 8C).  
       We further assessed the direct role of Foxo1-S273 phosphorylation in control of HGP, using 
the primary hepatocytes isolated from Foxo1-S273
A/A
, S273
D/D
, and WT mice. The basal level of 
HGP was increased by 46% in Foxo1-S273
D/D
 hepatocytes, but the basal potential was reduced 
by 40% in Foxo1-S273
A/A
 hepatocytes, compared to control hepatocytes (P<0.01, Fig. 8D). 
Upon glucagon stimulation, HGP was increased by 53% in control hepatocytes; however, this 
stimulatory effect was significantly impaired or attenuated by either Foxo1-S273D or S273A 
mutation, which exhibited an increase by 41% or 20%, respectively (P<0.01, Fig. 8D). 
Glucagon-stimulated glycogenolysis barely impaired by Foxo1 mutation in the cells.  
      We next performed glucagon tolerance tests in Foxo1-S273
A/A
, S273
D/D
, and WT mice in the 
fasting state. Both WT and Foxo1-S273
D/D
 mice exhibited a 1.8-fold increase  and Foxo1-
S273
A/A
 mice had a 1.6-fold increase in blood glucose after 15 min of glucagon injection, 
indicating that Foxo1-S273
A/A 
mutant impaired glucagon stimulation of blood glucose. 
Importantly, in WT and Foxo1-S273
A/A
 mice, blood glucose returned to initial level 60 min after 
glucagon injection, however, high blood glucose level was maintained in Foxo1-S273
D/D
 mice, 
indicating that Foxo1-S273
D/D
 mutant prolonged glucagon stimulation of blood glucose (P<0.05, 
Fig. 8 E and F). The impaired effects of glucagon stimulation on HGP and blood glucose by 
Foxo1 mutations at S273 suggest an important role of Foxo1-S273 phosphorylation plays in 
glucagon signaling in control of hepatic gluconeogenesis and blood glucose. 
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Foxo1-S273 phosphorylation increases in the liver of db/db and HFD-fed mice 
      Finally, we examined Foxo1-S273 phosphorylation in the liver of db/db diabetic mice, as 
well as HFD-induced insulin resistantmice. The db/db mice exhibited elevations in blood 
glucagon, glucose, and serum insulin by 3-fold, 3-fold, and 10-fold, respectively, compared to 
control mice (Fig. 8G).  Moreover, total Foxo1 protein and S273 phosphorylation significantly 
increased in the liver of db/db mice and accumulated in the nucleus (Fig. 8H). In parallel with 
increased Foxo1-S273 phosphorylation and PKA-T197 phosphorylation indicative of PKA 
activity, also markedly enhanced in both nucleus and cytoplasm in the liver of db/db mice (Fig. 
8I). The HFD-fed mice exhibited increased blood glucagon, glucose and serum insulin by 1.8-, 
1.4-, and 5-fold, respectively, compared to LFD-fed mice (Figure 8J). Moreover, total Foxo1 
protein and Foxo1-S273 phosphorylation significantly increased in liver of HFD-fed mice when 
compared to the LFD-fed liver (Fig.8, K andL). These data suggest that Foxo1-S273 
phosphorylation and its nuclear retention, along with excess glucagon and PKA activity, coexist 
in the liver of animals with T2D or insulin resistance.   
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DISCUSSION 
        We and other groups have previously established that insulin phosphorylates human Foxo1-
S256 by activation of Akt that promotes Foxo1 cytoplasmic sequestration or nuclear export, and 
then suppresses expression of genes responsible for HGP (12,18,20,21,35). In this study, using in 
vitro kinase assay-coupled LC/MS, phosphospecific antibodies, and CRISPR/Cas9–based Foxo1 
KI mutant mice, we were able to identify a novel molecular,  cellular and physiological 
mechanism by which Foxo1 mediates glucagon signaling via phosphorylation at Ser276  (human) 
or Ser273 (mouse) in control of hepatic gluconeogenesis and blood glucose.   
       Glucagon has been implicated in the pathogenesis of diabetic hyperglycemia, largely by 
enhancing HGP, which is believed to be a key mechanism for pathogenesis of diabetes mellitus 
(36). In mice with T2D, we recently demonstrated that hepatic Foxo1 deletion reduced HGP and 
blood glucose in db/db mice (16). Given that a high glucagon level is present in both types of 
diabetes (6), hyper-activation of Foxo1 by activated PKA and inactivated Akt upon insulin 
resistance or deficiency may serve as a fundamental mechanism for excess liver gluconeogenesis 
resulting in diabetic hyperglycemia.      
       The mechanism by which Foxo1-S276 phosphorylation promotes Foxo1 nuclear retention 
and stability is involved in the prevention of proteasome-mediated Foxo1 ubiquitination. We 
expect that Foxo1-S276 phosphorylation might enhance its recruitment with a number of co-
factors, such as importin or CREB, to participate in Foxo1 subcellular trafficking and gene 
transcription, but detailed molecular aspects warrant further investigation.  By activating 
heterologous signaling cascades, glucagon primarily activates PKA and downstream effectors, 
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including glycogen phosphorylase for glycogenolysis and CREB for gluconeogenesis (9,37). 
Glucagon also minimally activates Akt phosphorylation, but its duration and intensity seemed 
insufficient for induction of Foxo1-S256 phosphorylation and degradation (Fig. 2). Thus, insulin 
is a major hormone for the endogenous Akt activation downstream of the IRS1, 2-associated 
PI3K, as we observed in the liver or heart of male mice (15,26,38).  In this study, our in vitro 
data established that Foxo1-S276 is a target of PKA in glucagon signaling and promotes Foxo1 
nuclear retention. Foxo1-S276D mutation mimics Foxo1-S276 phosphorylation and promotes 
Foxo1 nuclear localization and stability. Moreover, Foxo1-S273D mutation impairs the ability of 
insulin-stimulated Foxo1 nuclear export or cytoplasmic sequestration. This finding suggests a 
novel mechanism for insulin resistance when Foxo1-S273 phosphorylated. Conversely, Foxo1-
S276A mutation, which blocks phosphorylation, enhances Foxo1 ubiquitination and/or 
degradation, a process reversed by the 28S proteasome inhibitor MG132.  This study reveals a 
unique mechanism of Foxo1 regulation by which glucagon stimulates HGP via Foxo1 at the 
post-translational level.   
       Foxo1 can be regulated by multiple protein kinases (15). It has been shown that mitogen-
activated protein kinase (MAPK) phosphorylates Foxo1 at S246, S284, S295, S326, S413, S415, 
S429, S467, S475 and T557, and p38α phosphorylates five of the ten sites-S284, S295, S326, 
S467 and S475 (39). Moreover, these phosphorylation sites are shared by CaMKII, and 
expression of a Foxo1-S7A mutation (S246A/S284A/S295A/S413A/S415A/S429A/S475A) 
attenuated glucagon-induced Foxo1 nuclear localization, and it is suggested that CaMKII 
promotes Foxo1 nuclear localization through p38α activation that stimulates hepatic 
gluconeogenesis (24,40). The Foxo1-S273 phosphorylation identified as a target of PKA is 
distinct from these sites, but whether it is involved by other protein kinases, such as p38α, remain 
to be determined.   
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      HGP is generally regulated by direct mechanisms of insulin action in hepatocytes 
autonomously (41). Our early studies suggest that direct hepatocytes signaling via IRS1, 2-
mediated Akt activation or hepatic Foxo1 suppression is required for hepatic insulin suppression 
on HGP and blood glucose (26). However, a recent report suggests that an indirect insulin that 
suppresses free fatty acid influx to hepatocytes from lipolysis of adipose tissue is critical for 
suppression of HGP so that hepatocyte Akt signaling is dispensable for HGP suppression (42). 
Indeed, HGP can be regulated by indirect insulin action in extrahepatic tissues non-
autonomously (41). In addition to suppress glucagon secretion from pancreatic α-cells or 
antagonize the effect of cAMP , insulin also suppresses HGP by the central nervous system 
(CNS) in hypothalamic neurons via a vagal efferent (43). Thus, we do not rule out the possibility 
of other tissues including CNS, adipose tissue, and pancreas on HGP control in the L-F1KO and 
KI mouse models, but our data from mouse primary hepatocytes do support that the cellular 
autonomous effect of glucagon in hepatocytes has critical roles in controlling Foxo1, 
gluconeogenesis, and HGP. 
      Foxo1 has a variety of target genes responsible for multiple physiological functions in the 
body (11,15,44,45). We have recently identified other two Foxo1 target genes in the liver, such 
as angiotensinogen, a precursor of angiotensin II (AngII) that regulates blood pressure (44). 
Foxo1 also promotes expression of heme oxygenase-1 (HO-1), reducing synthesis of heme and 
mitochondria (46) and driving bodily metabolic inflammation and insulin resistance in mice and 
humans (47).  In this study, we demonstrated a novel regulatory mechanism of Foxo1 by 
glucagon-cAMP-PKA signaling in hepatocytes, but we do not rule out the possibility of a similar 
Foxo1 regulation by other hormones via activation of PKA in tissues, including but not limited to 
glucagon (48). Indeed, hormones such as catecholamines or glucocorticoids also increases 
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hepatic gluconeogenesis or promote insulin resistance under certain conditions involving 
activation of PKA, such as stress (49). Our studies demonstrate that Foxo1 is a mediator of 
multiple signaling cascades, e.g. PKA and Akt; it integrates different hormones and intracellular 
protein kinases into the nuclear gene transcriptional programming in control of insulin sensitivity, 
HGP, blood glucose. Thus, Foxo1-S276 phosphorylation may not only serve as a novel and 
important biomarker for Foxo1 stability and bioactivity contributing to hyperglycemia upon 
development of diabetes mellitus, but also provide a potential therapeutic target in control of 
Foxo1 stability and activity to prevent diabetes mellitus and associated diseases in the future.           
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Figure 1. The effect of hepatic Foxo1 deletion on glucagon-induced glucose production and 
gluconeogenesis. (A) Blood glucose level in random-fed mice in 1h after i.p. injection of 0.25 
mg/kg body weight glucagon. . Ten-week-old mice per treatment. n = 6 mice per group. * 
P<0.05 vs control mice (CNTR); # P<0.05 for the comparison of designated groups. (B) 
Glucagon tolerance tests for mice after an 18 h overnight fasting. Blood glucose levels (mean ± 
SEM) were determined at the indicated time points after i.p. injection of 16 µg/kg body weight 
glucagon. n = 6 mice per group, * P<0.05 vs. CNTR. (C-E) Quantitative RT-PCR analyses of the 
livers of mice with i.p. injection of 0.25 mg/kg body glucagon for 1 h. n=3 mice per treatment. * 
P<0.05 vs. CNTR; # P<0.05 for the comparison of designated groups. (F) Hepatic glucose 
production (HGP), glycogenolysis, and gluconeogenesis in primary hepatocytes. Cells were 
isolated from wild-type (WT) or L-F1KO mice and cultured in DMEM with 2% FBS medium 
for attachment for 4 h, then switched to HGP buffer with or without pyruvate substrate. HGP 
were measured 3 h after 100 nM glucagon stimulation and normalized to total protein levels. n 
=3 per group. * P<0.05 vs. CNTR; # P<0.05 vs. L-F1KO.  
 
Figure 2. Regulation of Foxo1 stability and activity by insulin and glucagon in hepatocytes. 
(A) Insulin and glucagon signaling in HepG2 cells. Cells were cultured in DMEM with 10% FBS 
and then starved in DMEM with 1% BSA medium overnight prior to the treatment of 100 nM 
insulin or 100 nM glucagon over a 6 h time course.  Western-blotting was performed with 150 
µg protein of cell lysates to detect total Foxo1, Akt, CREB, pFoxo1-S256, pAkt-T308, and 
pCREB-S133. (B-E) Quantification of total Foxo1/GAPDH (B), p-Foxo1-S256/t-Foxo1 (C), 
pAKT-T308/Akt (D), and pCREB-S133/CREB (E) including from (A) was performed using 
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Image J. Results are presented as mean + SEM, * P<0.05 vs. 0 min treatment, n = 3 experiments. 
(F)The mRNA expression of  Foxo1 in HepG2 cells. HepG2 cells were cultured in DMEM with 
10% FBS and then starved in DMEM with 1% BSA medium overnight prior to the treatment of 
100 nM glucagon over a 6 h time course. The Foxo1 mRNA level was detected by qPCR, n=3 
experiments. 
 
Figure 3. Identification of novel phosphorylation sites of Foxo1 by PKA. (A) PKA activates 
and Akt inhibits Igfbp-1 promoter activity in cells. HepG2 cells were cultured in 6-well plate 
with DMEM with 10% FBS and then transfected with 0.5 µg Igfbp-1-Luc reporter gene and 0.1 
µg RL-luc internal control together with 0.5 µg expression vector for GFP, PKA catalytic 
subunit, Myr-Akt, HA-Foxo1, or a combination of two as designated.  Cell lysates were prepared 
for luciferase assays, and protein levels of PKA, Akt, Foxo1, or β-actin determined by Western-
blotting from 20 µg of total protein. n=3 experiments. Values are fold changes of luciferase 
activity relative to GFP group and presented as mean + SEM. * P<0.05 vs. GFP; # P<0.05 vs. 
Foxo1. (B) Putative phosphorylation sites of Foxo1 by PKA among different species. (C) PKA 
phosphorylates Foxo1 in vitro. 20 µg of recombinant Foxo1-GST was mixed with 5U (0.5 µg) 
recombinant active PKAc with or without 0.1 mM ATP, for 30 min at 30
◦
C; then the Foxo1-GST 
and PKAc were resolved in SDS-PAGE after the Coomassie-brilliant blue staining. The intact 
Foxo1-GST (105 kDa) or cleaved Foxo1 (60 kDa) were incised from the gel and subjected to 
LC-MS/MS. (D) MS/MS spectra of peptide containing S153 and S276 of Foxo1. Antibodies 
against phosphorylated Foxo1 at S153 and S276 were generated. (E-F) Phosphorylation of 
Foxo1-S276 and S153 by glucagon in cells. (E) HepG2 cells were  transfected with either 
scramble siRNA or siRNA-PKACB for 24 h, and then treated with or without 100 nM glucagon 
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for 60min.  Quantification of t-Foxo1, p-Foxo1-S276, p-Foxo1-S153, p-CREB, and CREB  was 
performed using Image J, and normalized by GAPDH. * P<0.05 vs. scramble siRNA; # P<0.05 
vs scramble siRNA+glucagon; n=3 experiments. (F) Primary hepatocytes were cultured and 
treated with either 100 nM glucagon or 10 µM 8-Br-cAMP for 30 min, or 10 µM PKA inhibitor 
H89 for 30 min prior to 60 min of 100 nM glucagon treatment. Phosphorylation of Foxo1-S150 
and S273 were analyzed by Western-blotting using antibodies at 1:500 dilution. Quantification 
of p-Foxo1-S273, p-Foxo1-S150, and t-Foxo1 was performed using Image J, and normalized by 
β-actin. * P<0.05 vs. vehicle; # P<0.05 vs glucagon; n=3 experiments.  
 
Figure 4. Glucagon promotes phosphorylation of Foxo1-S153 and S276 in vivo.  (A) 
Random-fed mice were i.p. injected with glucagon at 0.25 mg/kg body weight, and the liver was 
collected 15 min after injection to determine hepatic Foxo1 phosphorylation at S150 and S273 by 
using Western-blotting. Quantification of p-Foxo1-S273, p-Foxo1-S150 was performed using 
Image J, and normalized by β-actin.* P<0.05 vs. vehicle; # P<0.05 vs glucagon; n=4-6 mice per 
group. (B-D) 8-week WT Mice were i.v. injected with GCGR antagonist ([des-His
1
, Glu
9
]-
Glucagon amide) (1mg/kg body weight) after 6 h fasting, (B) blood glucose level was measured 
at the indicated time points, * P<0.05 vs. vehicle, n=4-6 mice per group; (C) area under the curve 
(AUC) from (B) was calculated, * P<0.05 vs. vehicle, n=4-6 mice per group; (D) liver was 
collected 45 min after [des-His
1
, Glu
9
]-Glucagon amide injection to determine hepatic total 
Foxo1 and Foxo1 phosphorylation at S150 and S273 by using Western-blotting. Quantification 
of total Foxo1 and p-Foxo1-S273, p-Foxo1-S150, p-CREB, and CREB was performed using 
Image J, and normalized by GAPDH.* P<0.05 vs. vehicle, n=4-6 mice per group.  
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Figure 5. Foxo1-S276 phosphorylation controls cAMP-induced Foxo1 nuclear localization 
in hepatocytes.  HepG2 cell were transfected with 5 µg plasmid DNA expressing GFP-Foxo1-
WT, S276A, S276D, S153A, or S153D for 18 h, and then treated with/without 10 µM cAMP for 
30 min. GFP-positive cells were displayed, DAPI for nucleus stained, and analyzed under 
confocal microscope. Representative images are shown.     
 
Figure 6. Glucagon or cAMP stimulates Foxo1 nuclear localization and Foxo1-S276 
phosphorylation enhancing Foxo1 stability in hepatocytes. (A) HepG2 cells were transfected 
with 5 µg plasmid DNA expressing HA-Foxo1 for 18 h, and then treated with 100 nM glucagon 
(Glc), 10 µM cAMP or 100 nM insulin for 30 min prior to extraction of nuclear (N) and 
cytoplasmic proteins (C). 20 µg nuclear protein or 100 µg cytoplasmic protein was 
immunoblotted to determine the abundance of total Foxo1 in nucleus or cytoplasm. Signal 
intensity was quantified by image J software for statistical comparison. Cytoplasmic and nuclear 
protein level were normalized by GAPDH and Histone H1, respectively. n=3 experiments. * 
P<0.05 vs. vehicle in cytoplasm; # P<0.05 vs. vehicle in nucleus. (B and C) Distribution of 
Foxo1-S276 mutant proteins in the nucleus and cytoplasm of cells.  HepG2 cells were 
transfected with 5 µg plasmid DNA expressing Foxo1-WT, S276A, or S276D for 18 h and then 
treated with/without 100 nM glucagon for 30 min. Nuclear (N) or cytoplasmic protein (C) was 
extracted to determine protein abundance of Foxo1-S276 mutants in nucleus and cytoplasm. 
Representative images are shown in (B and C), and Signal intensity was quantified by image J 
software for statistical comparison. n=3 experiments. * P<0.05 vs. vehicle in cytoplasm; # 
P<0.05 vs. vehicle in nucleus.  (D) Foxo1-S276 mutations influence Foxo1 stability in a 
proteasome-dependent manner. Western-blotting was performed to detect total Foxo1 abundance 
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in HepG2 cells that was transfected with the same amount of plasmid DNA expressing Foxo1-
WT, S276A or S276D for 10 h and cells were then starved for 8 h, and treated with 10 µM 
cycloheximide or 10 µg/ml MG132 for 6 h prior cellular protein collection. Representative 
images are shown. Signal intensity  was quantified and normalized by a-actinin for statistical 
analysis. * P<0.05 vs. Foxo1-WT; # P<0.05 for the comparison of designated groups. n=3 
different experiment. (E) Foxo1-S276 mutations influence insulin induced Foxo1 ubiquitination. 
HepG2 cells were co-transfected with eGFP expression vectors encoding wild-type FoxO1, 
FoxO1-S276D or FoxO1-S276A and/or FLAG-ubiquitin for 10 h and starve cells for 12 h, and 
then treated with 100 nM insulin for 12 h. Quantification of t-Foxo1 normalized by α-actinin was 
performed using Image J.  * P<0.05 vs. Foxo1-WT and FLAG-ubiquitin group; # P<0.05 for 
comparison of designated groups. n=3 different experiment. 
 
Figure 7. Foxo1-S276D impairs insulin-stimulated Foxo1 nuclear export in hepatocytes. (A) 
HepG2 cells were transfected with 5 µg plasmid DNA expressing eGFP-Foxo1-WT or eGFP-
Foxo1-S276D for 18 h, and cells were then serum starved for 8 h prior to 100 nM insulin 
treatment for 0 min, 30 min, 90 min or 120 min. The GFP-positive cells were displayed, DAPI 
for nucleus stained, and analyzed under the confocal microscope. Representative images are 
shown.  (B) HepG2 cells were transfected with 10 µg eGFP expression vectors encoding Foxo1-
WT or Foxo1-S276D for 18 h and followed by 8 h serum starvation prior to 100 nM insulin 
stimulation for 90 min and 120 min. Western-blotting was performed for total Foxo1 and 
phospho-Foxo1-S256 in cytoplasm and nucleus. (C) Quantification of total Foxo1 and pFoxo1-
S256/t-Foxo1 was performed by image J. Cytoplasmic and nuclear protein level were normalized 
by GAPDH and Histone H1, respectively. Results are presented as mean ± SEM, n=3 different 
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experiments. * P<0.05 vs. 0 min of insulin treatment from Foxo1-WT in cytoplasm; # P<0.05 vs. 
0 min of insulin treatment from Foxo1-WT in nucleus. 
 
Figure 8. Foxo1-S273 mutations impair blood glucose and hepatic glucose production in 
mice. (A) Blood glucose levels of random-fed or 18 h fasted mice. n = 4-6 mice per genotype. * 
P<0.05 vs. WT mice. (B) Quantitative PCR analysis of expression of Igfbp-1 and G6pc in the 
liver of 18h fasted mice, n=4 mice per genotype, * P<0.05 vs. WT mice. (C) Foxo1 protein 
levels in the livers of the mutant mice. Western-blotting results from two mice per genotype are 
shown representatively. * P<0.05, ** P<0.01 vs. WT. n=4 per group. (D) HGP assays in the 
primary hepatocytes isolated from WT, Foxo1-S273
A/A
, and Foxo1-S273
D/D
 knock-in mice. 
Fresh hepatocytes were isolated from these mice and HGP were measured 3 h after 100 nM 
glucagon stimulation and normalized to total protein levels. n= 3 per treatment. * P<0.05 vs WT 
with vehicle group. # P<0.05 for the comparison of designated groups. (E-F) Glucagon tolerance 
test, (E) Glucagon tolerance tests for mice after an 18 h overnight fasting. Blood glucose levels 
(mean ± SEM) were determined at the indicated time points after i.p. injection of 16 µg/kg body 
weight glucagon. n = 6 mice, * P<0.05 vs. WT; (F) Area under the curve (AUC) from (E) was 
calculated. * P<0.05 vs. WT, n=4-6 per group. (G) Blood glucagon, insulin and glucose levels in 
WT and db/db mice in an 18 h fasting state. * P<0.05 vs. WT, n=4 mice per group. (H) pFoxo1-
S273, pFoxo1-S253, total Foxo1, pPKA-T179, PKA, histone H1, and GAPDH in 100 µg 
cytoplasmic protein (C) and 20 µg nuclear proteins (N) of mouse livers were determined by 
Western-blotting. (I) Quantification of pFoxo1-S273, p-S253, total Foxo1, pPKA-T197, or PKA 
was performed by image J. The cytoplasmic and nuclear protein level were normalized by 
GAPDH and Histone H1, respectively. * P<0.05 vs. WT, n=3 mice per group. Results are shown 
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as mean + SEM.  (J) Blood glucagon, insulin and glucose levels in LFD- and HFD-fed WT mice 
in an 18 h fasting state. * P<0.05 vs. LFD, n=4 mice per group. (K) pFoxo1-S273, total Foxo1, 
pCREB, and CREB level of mouse livers were determined by Western-blotting. (L) 
Quantification of pFoxo1-S273, total Foxo1, pCREB, and CREB was performed by image J.. * 
P<0.05 vs. LFD, n=4 mice per group. Results are shown as mean + SEM. 
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SUPPLEMENTAL MATERIAL 
Liquid Chromatography-mass spectrometry (LC-MS). To identify the 
phosphorylation sites of Foxo1, we performed LC-MS/MS analysis. The specific bands 
on the SDS-PAGE gel after Coomassie-brilliant blue staining were excised, cut into 
several pieces, and subjected to dimethyl formamide (DMF)-assisted trypsin digestion. 
The digested peptides were analyzed by LC-MS/MS. Briefly, the pieces of the gel was 
dissolved in 50 mM NH4HCO3 buffer (pH8.0) containing 40% DMF and added with 20 
µl of 2 µg trypsin, and incubated overnight at 37 °C. After digestion, the solution was 
further diluted by adding three-fold volume of deionized water. After centrifugation, the 
supernatant was collected. The debris were washed in 80 µL of 70% acetonitrile and 1% 
rifluoroacetic acid with sonication for 30 min and then centrifuged. Both supernatants 
were combined and concentrated in a Speed-Vac and stored at -20 °C until further use. 
To identify the unknown proteins and phosphorylation sites (p-sites), HPLC conjugated 
electrospray ionization (ESI) ion trap mass spectrometry were employed. The samples 
were separated on an Alltech Vydac MS C18 column (300 A, 5µm, 100 mm × 300 µm) 
at a flow rate of 5µl/min using a mobile phase of (A) 0.1% v/v formic acid in water and 
(B) 0.1% v/v formic acid in acetonitrile. The chromatography system was directly 
coupled to an ESI Ion-trap mass spectrometer. Raw spectrum data were processed and 
MASCOT-compatible mgf files were created using DataAnalysis software (Bruker 
Daltonics).  Peptide searching and analysis were performed using MASCOT software 
(Matrixscience, London, UK). The NCBI gene bank database was used for protein 
identification.  
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Generation of phosphospecific antibodies for Foxo1. The conjugated peptides were 
used to immunize rabbits. Six weeks later serum was collected and passed through a CH-
sepharose column containing beads coupled to dephospho-peptide antigen, followed by 
affinity chromatography on the column with beads covalently coupled to phosphor-
peptide antigen. Phosphospecific antibodies were eluted with 0.1 M glycine, pH 2.4, 
immediately adjusted to pH 8.0 with Tris-base and stored at -20ºC. The phosphospecific 
antibodies was passed quality control tests, in which 50% titer Elisa test was used to 
determine signal intensity. The reference of 153,000 for antibody against pFoxo1-S276 
and 105,000 for antibody against pFoxo1-S153 achieved, indicative for high specificity 
signals to corresponding specific phosphorylation sites, in comparison with control non-
phosphorylated peptides as reference of signal less than 100 . 
Chemicals. Insulin, 8-Br-cAMP, glucagon, [des-His
1
, Glu
9
]-Glucagon amide, MG132, 
and CHX were purchased from Sigma; Foxo1, pFoxo1-S256, Akt, pAkt-T308, PKA, 
pPKA-T197, and β-actin antibodies were from Cell Signaling Technology. Antibodies 
specific for CREB, pCREB-S133, Histone H1, and β-actin were from Santa Cruz. The 
scramble siRNA (AM4611) and siRNA-PKACB (4390824) were purchased from 
Thermo Fisher (Waltham, MA).  
PKA knock-down assay. HepG2 cells were cultured with DMEM with 10% FBS for 6 h. 
Cell culture were then subjected to Lipofectamine® 3000 (Life technologies) with 
scramble siRNA or siRNA-PKACB according to manufacturer’s instruction. 24 h after 
transfection, cells were subjected to further treatment. 
Generation of Foxo1-S273A and Foxo1-S273D Knock-in mice. Mouse Foxo1 gene 
(Ensembl: ENSMUSG00000044167) is located on mouse chromosome 3. Three exons 
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have been identified, with the ATG start codon in exon 1 and TAA stop codon in exon 2. 
The Foxo1-S273 is located in exon 2 and selected as target sites. The gRNA was 
designed and the targeting vectors constructed, and oligo donors with targeting sequence 
flanked by 60bp homologous sequences were designed. The S273A (TCT to GCT), 
S273D (TCT to GAT) mutation site in the donor oligo was introduced into exon 2 by 
homology-directed repair. The Cas9 mRNA and gRNA were generated by in vitro 
transcription and oligo donor was co-injected into fertilized eggs for the KI mouse 
production.  
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Figure  S1 
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Specific primers: mFoxo1-gRNA-SPF: 
GGGGGAGTGCTGCACTTCTAACATA 
DNA Sequencing Primer (Forward Sequencing): 5’-
 
S273 +/+ 
S273A/
S273 
C 
A/+ 
Mic
A/Χ 
+ ○ 
↗ 
○ 
+/+    A/+  
D/+ D/Χ 
+ ○ 
↗ 
○ 
+/+    D/+  
B 
gRNA2: TCTCTCCAGTCTGGGCAAGAGGG 
Oligo 1 A mutation 
TCCATGGACAACAACAGTAAATTTGCTAAGAGCCGAGG
GCGGGCTGCTAAGAAAAAAGCAGCTCTtCAGTCTGGG
CAAGAGGGTCCTGGAGACAGCCCTGGGTCTCAGTTTT
CTAAGTGGCCTGCG  
Oligo 2 D mutation  
TCCATGGACAACAACAGTAAATTTGCTAAGAGCCGAGG
GCGGGCTGCTAAGAAAAAAGCAGATCTtCAGTCTGGGC
AAGAGGGTCCTGGAGACAGCCCTGGGTCTCAGTTTTC
TAAGTGGCCTGCG 
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Figure S1. DNA sequencing of Foxo1-S273A and Foxo1-S273D heterozygotes and 
homozygotes in mice. (A) Construction of plasmid DNA expressing Foxo1 guidance 
RNA with human Cas9 expression vector. (B) Sequencing results of Foxo1 alleles from 
+/+ (wild-type or WT), A/+, and D/+ heterozygous founder mice. (C) The breeding 
strategy and genotyping for Foxo1-S273
+/+
, S273
A/A
, and S273
D/D
 alleles in mice. 
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